The authors would like to thank Bilal Khorsheed from Lena nanoceutics for supplying the nano-suspensions. Also we thank Yuling Ma and Clive Ellory for their help in the preliminary work on electrophysiology.
1 J. H. Park, D. C. McMillan, P. G. Horgan, and C. S. Roxburgh, The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 40, 68-77 (2014)
2 M. Hussain, A. Javeed, M. Ashraf, N. Al-Zaubai, A. Stewart, and M. M. Mukhtar, Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacol Res. 66, 7-18 (2012)
3 B. Pasche, Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA. 309, 2598-9 (2013)
4 D. Mansouri, D. C. McMillan, C. S. Roxburgh, E. M. Crighton, and P. G. Horgan, The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. Br J Cancer. 109, 249-56 (2013)
5 N. R. Cook, I. M. Lee, S. M. Zhang, M. V. Moorthy, and J. E. Buring, Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 159, 77-85 (2013)
6 J. A. Baron, Aspirin and NSAIDs for the prevention of colorectal cancer. Recent Results Cancer Res. 181, 223-9 (2009)
7 J. Burn, A. M. Gerdes, F. Macrae, J. P. Mecklin, G. Moeslein, S. Olschwang, D. Eccles, D. G. Evans, E. R. Maher, L. Bertario, M. L. Bisgaard, M. G. Dunlop, J. W. Ho, S. V. Hodgson, A. Lindblom, J. Lubinski, P. J. Morrison, V. Murday, R. Ramesar, L. Side, R. J. Scott, H. J. Thomas, H. F. Vasen, G. Barker, G. Crawford, F. Elliott, M. Movahedi, K. Pylvanainen, J. T. Wijnen, R. Fodde, H. T. Lynch, J. C. Mathers, and D. T. Bishop, Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 378, 2081-7 (2011)
8 J. Burn, J. Mathers, and D. T. Bishop, Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res. 191, 157-83 (2013)
9 B. L. Seufert, E. M. Poole, J. Whitton, L. Xiao, K. W. Makar, P. T. Campbell, R. J. Kulmacz, J. A. Baron, P. A. Newcomb, M. L. Slattery, J. D. Potter, and C. M. Ulrich, IkappaBKbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis. 34, 79-85 (2013)
10 R. R. Brady, C. J. Loveridge, M. G. Dunlop, and L. A. Stark, c-Src dependency of NSAID-induced effects on NF-kappaB-mediated apoptosis in colorectal cancer cells. Carcinogenesis. 32, 1069-77 (2011)
11 A. E. Coghill, A. I. Phipps, A. A. Bavry, J. Wactawski-Wende, D. S. Lane, A. LaCroix, and P. A. Newcomb, The association between NSAID use and colorectal cancer mortality: results from the women's health initiative. Cancer Epidemiol Biomarkers Prev. 21, 1966-73 (2012)
12 T. Kawahara, H. Ishiguro, K. Hoshino, J. Teranishi, Y. Miyoshi, Y. Kubota, and H. Uemura, Analysis of NSAID-activated gene 1 expression in prostate cancer. Urol Int. 84, 198-202 (2010)
13 S. U. Kang, B. S. Lee, S. H. Lee, S. J. Baek, Y. S. Shin, and C. H. Kim, Expression of NSAID-activated gene-1 by EGCG in head and neck cancer: involvement of ATM-dependent p53 expression. J Nutr Biochem. 24, 986-99 (2013)
14 W. Tian, Y. Zhao, S. Liu, and X. Li, Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev. 19, 288-98 (2010)
15 T. M. Brasky, M. R. Bonner, K. B. Moysich, H. M. Ochs-Balcom, C. Marian, C. B. Ambrosone, J. Nie, M. H. Tao, S. B. Edge, M. Trevisan, P. G. Shields, and J. L. Freudenheim, Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 126, 157-65 (2011)
16 M. Retsky, R. Rogers, R. Demicheli, W. J. Hrushesky, I. Gukas, J. S. Vaidya, M. Baum, P. Forget, M. Dekock, and K. Pachmann, NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 134, 881-8 (2012)
17 W. Liu, Y. Park, M. P. Purdue, E. Giovannucci, and E. Cho, A large cohort study of nonsteroidal anti-inflammatory drugs and renal cell carcinoma incidence in the National Institutes of Health-AARP Diet and Health Study. Cancer Causes Control. 24, 1865-73 (2013)
18 R. R. Tice, E. Agurell, D. Anderson, B. Burlinson, A. Hartmann, H. Kobayashi, Y. Miyamae, E. Rojas, J. C. Ryu, and Y. F. Sasaki, Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 35, 206-21 (2000)
19 M. Fenech, Cytokinesis-block micronucleus cytome assay. Nat Protoc. 2, 1084-104 (2007)
20 R. J. Albertini, D. Anderson, G. R. Douglas, L. Hagmar, K. Hemminki, F. Merlo, A. T. Natarajan, H. Norppa, D. E. Shuker, R. Tice, M. D. Waters, and A. Aitio, IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. International Programme on Chemical Safety. Mutat Res. 463, 111-72 (2000)
21 M. Najafzadeh, A. Baumgartner, R. Gopalan, J. B. Davies, A. Wright, P. D. Reynolds, and D. Anderson, In vitro sensitivities to UVA of lymphocytes from patients with colon and melanoma cancers and precancerous states in the micronucleus and the Comet assays. Mutagenesis. 27, 351-7 (2012)
22 D. Anderson, M. Najafzadeh, R. Gopalan, N. Ghaderi, A. J. Scally, S. T. Britland, B. K. Jacobs, P. D. Reynolds, J. Davies, A. L. Wright, S. Al-Ghazal, D. Sharpe, and M. C. Denyer, Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics. FASEB J. 28, 4563-70 (2014)
23 T. S. Kumaravel, B. Vilhar, S. P. Faux, and A. N. Jha, Comet Assay measurements: a perspective. Cell Biol Toxicol. 25, 53-64 (2009)
24 T. S. Kumaravel, and A. N. Jha, Reliable Comet assay measurements for detecting DNA damage induced by ionising radiation and chemicals. Mutat Res. 605, 7-16 (2006)